Arvinas screens cheap on traditional value metrics with meaningful modeled upside, but weak quality metrics, heavy cash burn, and volatile earnings temper the case for a small, institutionally under-followed biotech.
Thesis pillars
- Attractively Valued Vs Target↓Deteriorating
- Quality Below Engine Floor↑Improving
- Institutionally Constrained Upside↑Improving
- +2 more pillars — see the Why tab for full reasoning
Arvinas, Inc. (ARVN) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.98, but acceptable to hold if already in. Reason: Below 200-day MA.
Arvinas is a clinical-stage biotechnology company using its PROTAC protein-degrader platform to develop small-molecule therapies for oncology and neurology, with five clinical-stage candidates including vepdegestrant, co-developed with Pfizer for ER+/HER2-, ESR1-mutated... Read more
Hold if already holding. Not a fresh buy at $8.98, but acceptable to hold if already in. Reason: Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 62. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Arvinas, Inc.
About Arvinas, Inc.
Arvinas has advanced five product candidates from its PROTAC protein-degradation platform into clinical development, led by vepdegestrant, co-developed with Pfizer for ER+/HER2-, ESR1-mutated metastatic breast cancer, which the FDA accepted for review with a PDUFA date of June 5, 2026. The company has no approved products and also advances ARV-102, an oral LRRK2 degrader in Phase 1 trials for Parkinson's disease and progressive supranuclear palsy, alongside earlier-stage KRAS-G12D, BCL6, and androgen-receptor-targeted candidates.
Arvinas generates no product revenue and instead funds development through equity financings and payments from collaborators: an early-stage discovery partnership with Pfizer and Genentech/Roche, and an out-license of luxdegalutamide to Novartis that could yield milestone and royalty payments. Vepdegestrant's commercial path depends on Arvinas and Pfizer jointly selecting a third-party partner for commercialization, a decision the companies announced they were pursuing together in the third quarter of 2025 rather than committing to launch the drug themselves. The company's PROTAC Discovery Engine, which pairs proprietary E3-ligase ligand libraries, machine-learning tools, and DNA-encoded-library screening, is designed to be compatible with conventional small-molecule manufacturing processes rather than the complex biologics infrastructure larger degrader or cell-therapy competitors require, an advantage Arvinas cites as supporting scalability and cost control across its entire pipeline, not just vepdegestrant.
Show full overview
Even with a five-program clinical pipeline, Arvinas faces a concentrated near-term catalyst: the FDA's PDUFA action date for vepdegestrant is June 5, 2026, and the drug's ultimate commercial value depends not just on that approval decision but on Arvinas and Pfizer successfully recruiting a third-party partner to commercialize it, a search the companies had not resolved as of the filing. A rejection, delay, or a disappointing commercialization-partner outcome would remove the platform's most advanced value driver just as ARV-102's Parkinson's and progressive supranuclear palsy data remain early-stage, leaving the company's near-term narrative more concentrated in a single regulatory decision than its five-candidate pipeline might suggest.
See also: Healthcare · Biotechnology
From Arvinas, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-08-11Recent Developments — Arvinas, Inc.
Latest news
- NEWS Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14 — benzinga Aug 10, 2026 positive
- NEWS Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21 — benzinga Aug 10, 2026 neutral
- NEWS Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11 — benzinga Aug 5, 2026 negative
- NEWS Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12 — benzinga Aug 5, 2026 positive
- NEWS BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target — benzinga Aug 4, 2026 positive
Generated 2026-08-14T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-22Item 5.02MEDIUMChief Medical Officer Dr. Noah Berkowitz agreed to depart effective July 3, 2026 to pursue other opportunities; a search for his replacement is underway and he entered a separation agreement with severance benefits.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.98, but acceptable to hold if already in. Reason: Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 62. Maintain position. Not compelling to add more. Target $12.18 (+35.6%), stop $8.36 (−7.4%), A.R:R 2.9:1. Score 6.2/10, moderate confidence.
Take-profit target: $12.18 (+35.6% upside). Target $12.18 (+35.6%), stop $8.36 (−7.4%), A.R:R 2.9:1. Stop-loss: $8.36.
Below 200-day MA.
Arvinas, Inc. trades at a P/E of 33.3 (forward -2.9). TrendMatrix value score: 8.0/10. Verdict: Hold.
23 analysts cover ARVN with a consensus score of 3.7/5. Average price target: $14.
What does Arvinas, Inc. do?Arvinas is a clinical-stage biotechnology company using its PROTAC protein-degrader platform to develop small-molecule...
Arvinas is a clinical-stage biotechnology company using its PROTAC protein-degrader platform to develop small-molecule therapies for oncology and neurology, with five clinical-stage candidates including vepdegestrant, co-developed with Pfizer for ER+/HER2-, ESR1-mutated metastatic breast cancer, and ARV-102, an oral LRRK2 degrader for Parkinson's disease. The FDA accepted vepdegestrant's NDA with a PDUFA action date of June 5, 2026, and the company has no approved products, collaborating with Pfizer, Genentech, and Novartis to help fund and advance its pipeline.